What's Happening?
Antengene Corporation Limited has received endorsement from China's Center for Drug Evaluation (CDE) to initiate a pivotal Phase III clinical trial, known as CLINCH-3, for ATG-022. This study targets patients with CLDN18.2+ advanced gastric or gastroesophageal
junction adenocarcinoma. The trial, led by Prof. Lin Shen from Peking University Cancer Hospital, is designed to evaluate the efficacy and safety of ATG-022 compared to the treatment of the investigator's choice. The primary endpoints are progression-free survival and overall survival, with secondary endpoints including objective response rate and safety. The study follows promising results from earlier phases, where ATG-022 showed a differentiated efficacy and safety profile.
Why It's Important?
The initiation of the CLINCH-3 study marks a significant step in addressing the unmet medical needs of patients with advanced gastric cancer, a condition with limited effective treatment options. The study's outcomes could potentially transform the treatment landscape for this type of cancer, offering a new monotherapy option. Success in this trial could lead to a marketing approval application for ATG-022, providing a new hope for patients and potentially setting a new standard in cancer treatment. The study also highlights Antengene's capabilities in drug development and its commitment to advancing cancer therapies.
What's Next?
Antengene plans to advance a comprehensive clinical development strategy for ATG-022, including ongoing combination studies with anti-PD-1 therapy and chemotherapy in first-line gastric cancer settings. The company aims to explore the drug's potential in other CLDN18.2+ solid tumors. The results of the CLINCH-3 study will be crucial in determining the next steps for regulatory approval and potential commercialization. Antengene's efforts could lead to broader applications of ATG-022, impacting treatment protocols globally.
